Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz

Logo MUG-Forschungsportal


Suchbegriffe: GEMCITABINE, . Treffer: 45


Riedl, JM; Schwarzenbacher, E; Moik, F; Horvath, L; Gantschnigg, A; Renneberg, F; Posch, F; Barth, DA; Stotz, M; Pichler, M; Hatzl, S; Fandler-Höfler, S; Gressenberger, P; Gary, T; Jost, PJ; Greil, R; Ay, C; Djanani, A; Gerger, A; Schlick, K Patterns of Thromboembolism in Patients with Advanced Pancreatic Cancer Undergoing First-Line Chemotherapy with FOLFIRINOX or Gemcitabine/nab-Paclitaxel.
Thromb Haemost. 2022; 122(4):633-645 Doi: 10.1055/a-1548-4847
Web of Science PubMed FullText FullText_MUG



Posch, F; Prinz, F; Balihodzic, A; Mayr, C; Kiesslich, T; Klec, C; Jonas, K; Barth, DA; Riedl, JM; Gerger, A; Pichler, M MiR-200c-3p Modulates Cisplatin Resistance in Biliary Tract Cancer by ZEB1-Independent Mechanisms.
Cancers (Basel). 2021; 13(16): Doi: 10.3390/cancers13163996 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Prager, GW; Oehler, L; Gerger, A; Mlineritsch, B; Andel, J; Petzer, A; Wilthoner, K; Sliwa, T; Pichler, P; Winder, T; Heibl, S; Gruenberger, B; Laengle, F; Hubmann, E; Korger, M; Pecherstorfer, M; Djanani, A; Neumann, HJ; Philipp-Abbrederis, K; Wöll, E; Trondl, R; Arnold-Schrauf, C; Eisterer, W Comparison of nab-paclitaxel plus gemcitabine in elderly versus younger patients with metastatic pancreatic cancer: Analysis of a multicentre, prospective, non-interventional study.
Eur J Cancer. 2021; 143:101-112 Doi: 10.1016/j.ejca.2020.11.003 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Riedl, JM; Posch, F; Horvath, L; Gantschnigg, A; Renneberg, F; Schwarzenbacher, E; Moik, F; Barth, DA; Rossmann, CH; Stotz, M; Schaberl-Moser, R; Pichler, M; Stöger, H; Greil, R; Djanani, A; Schlick, K; Gerger, A Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis.
Eur J Cancer. 2021; 151: 3-13. Doi: 10.1016/j.ejca.2021.03.040 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Waldherr, L; Seitanidou, M; Jakesova, M; Handl, V; Honeder, S; Nowakowska, M; Tomin, T; Rad, MK; Schmidt, T; Distl, J; Birner-Gruenberger, R; Campe, G; Schafer, U; Berggren, M; Rinner, B; Asslaber, M; Ghaffari-Tabrizi-Wizsy, N; Patz, S; Simon, DT; Schindl, R Targeted Chemotherapy of Glioblastoma Spheroids with an Iontronic Pump
ADV MATER TECHNOL-US. 2021; 2001302 Doi: 10.1002/admt.202001302 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Zalyte, E; Dedonyte, V; Kurlinkus, B; Sileikis, A; Schemmer, P; Valius, M Establishment and Characterization of a New Pancreatic Ductal Adenocarcinoma Cell Line Capan-26.
ANTICANCER RES. 2021; 41(3): 1401-1406. Doi: 10.21873/anticanres.14897
Web of Science PubMed FullText FullText_MUG



Moik, F; van, Es, N; Posch, F; Di, Nisio, M; Fuereder, T; Preusser, M; Pabinger, I; Ay, C Gemcitabine and Platinum-Based Agents for the Prediction of Cancer-Associated Venous Thromboembolism: Results from the Vienna Cancer and Thrombosis Study.
Cancers (Basel). 2020; 12(9): Doi: 10.3390/cancers12092493 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Riedl, JM; Posch, F; Prager, G; Eisterer, W; Oehler, L; Sliwa, T; Wilthoner, K; Petzer, A; Pichler, P; Hubmann, E; Winder, T; Burgstaller, S; Korger, M; Andel, J; Greil, R; Neumann, HJ; Pecherstorfer, M; Philipp-Abbrederis, K; Djanani, A; Gruenberger, B; Laengle, F; Wöll, E; Gerger, A The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of an Austrian multicenter, noninterventional study.
Ther Adv Med Oncol. 2020; 12: 1758835919900872-1758835919900872. Doi: 10.1177/1758835919900872 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Lorusso, D; Hilpert, F; González Martin, A; Rau, J; Ottevanger, P; Greimel, E; Lück, HJ; Selle, F; Colombo, N; Kroep, JR; Mirza, MR; Berger, R; Pardo, B; Grischke, EM; Berton-Rigaud, D; Martinez-Garcia, J; Vergote, I; Redondo, A; Cardona, A; Bastière-Truchot, L; du Bois, A; Kurzeder, C; PENELOPE trial investigators Patient-reported outcomes and final overall survival results from the randomized phase 3 PENELOPE trial evaluating pertuzumab in low tumor human epidermal growth factor receptor 3 (HER3) mRNA-expressing platinum-resistant ovarian cancer.
INT J GYNECOL CANCER. 2019; 29(7): 1141-1147. Doi: 10.1136/ijgc-2019-000370
Web of Science PubMed FullText FullText_MUG


Retrosi, C; Vezzoni, R; Conforti, C; Corneli, P; Magaton-Rizzi, G; Zalaudek, I; Di, Meo, N Targetoid erythema surrounding multiple seborrheic keratoses induced by chemotherapy with gemcitabine.
Acta Dermatovenerol Alp Pannonica Adriat. 2019; 28(4): 185-186. Doi: 10.15570/actaapa.2019.44 (- Case Report)
Web of Science PubMed FullText FullText_MUG


Scheithauer, W; Putora, PM; Grünberger, B; Eisterer, W; Wöll, E; Prager, G; Schaberl-Moser, R; Greil, R; Glatzer, M Patterns of care in metastatic pancreatic cancer: patient selection in clinical routine.
Therap Adv Gastroenterol. 2019; 12(5):1756284819877635-1756284819877635 Doi: 10.1177/1756284819877635 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Cerroni, L Mycosis fungoides-clinical and histopathologic features, differential diagnosis, and treatment.
SEMIN CUTAN MED SURG. 2018; 37(1): 2-10. Doi: 10.12788/j.sder.2018.002
Web of Science PubMed FullText FullText_MUG


Hann, A; Nosalski, E; Hermann, PC; Egger, J; Seufferlein, T; Keller, F Chemotherapeutic agents eligible for prior dosing in pancreatic cancer patients requiring hemodialysis: a systematic review
Clin Nephrol. 2018; 90(2):125-141 Doi: 10.5414/CN109327
Web of Science PubMed FullText FullText_MUG



Ugurel, S; Loquai, C; Terheyden, P; Schadendorf, D; Richtig, E; Utikal, J; Gutzmer, R; Rass, K; Sunderkotter, C; Stein, A; Fluck, M; Kaatz, M; Trefzer, U; Kahler, K; Stadler, R; Berking, C; Holler, C; Kerschke, L; Edler, L; Kopp-Schneider, A; Becker, JC Chemosensitivity-directed therapy compared to dacarbazine in chemo-naive advanced metastatic melanoma: a multicenter randomized phase-3 DeCOG trial
ONCOTARGET. 2017; 8(44): 76029-76043. Doi: 10.18632/oncotarget.18635 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG



Al-Assar, O; Bittner, MI; Lunardi, S; Stratford, MR; McKenna, WG; Brunner, TB The radiosensitizing effects of Nelfinavir on pancreatic cancer with and without pancreatic stellate cells.
Radiother Oncol. 2016; 119(2):300-5 Doi: 10.1016/j.radonc.2016.03.024
Web of Science PubMed FullText FullText_MUG


Czink, E; Heining, C; Weber, TF; Lasitschka, F; Schemmer, P; Schirmacher, P; Weiss, KH; Glimm, H; Brors, B; Weichert, W; Jäger, D; Fröhling, S; Springfeld, C [Durable remission under dual HER2 blockade with Trastuzumab and Pertuzumab in a patient with metastatic gallbladder cancer].
Z Gastroenterol. 2016; 54(5):426-430 Doi: 10.1055/s-0042-103498
Web of Science PubMed FullText FullText_MUG


Fan, P; Liu, L; Yin, Y; Zhao, Z; Zhang, Y; Amponsah, PS; Xiao, X; Bauer, N; Abukiwan, A; Nwaeburu, CC; Gladkich, J; Gao, C; Schemmer, P; Gross, W; Herr, I MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer.
Cancer Lett. 2016; 373(1):130-137 Doi: 10.1016/j.canlet.2016.01.038
Web of Science PubMed FullText FullText_MUG


Fan, P; Zhang, Y; Liu, L; Zhao, Z; Yin, Y; Xiao, X; Bauer, N; Gladkich, J; Mattern, J; Gao, C; Schemmer, P; Gross, W; Herr, I Continuous exposure of pancreatic cancer cells to dietary bioactive agents does not induce drug resistance unlike chemotherapy.
Cell Death Dis. 2016; 7(6):e2246-e2246 Doi: 10.1038/cddis.2016.157 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Hepp, P; Andergassen, U; Jäger, B; Trapp, E; Alunni-Fabbroni, M; Friedl, TW; Hecker, N; Lorenz, R; Fasching, P; Schneeweiss, A; Fehm, T; Janni, W; Rack, B Association of CA27.29 and Circulating Tumor Cells Before and at Different Times After Adjuvant Chemotherapy in Patients with Early-stage Breast Cancer - The SUCCESS Trial.
Anticancer Res. 2016; 36(9):4771-4776 Doi: 10.21873/anticanres.11034 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Jagadeeshan, S; Subramanian, A; Tentu, S; Beesetti, S; Singhal, M; Raghavan, S; Surabhi, RP; Mavuluri, J; Bhoopalan, H; Biswal, J; Pitani, RS; Chidambaram, S; Sundaram, S; Malathi, R; Jeyaraman, J; Nair, AS; Venkatraman, G; Rayala, SK P21-activated kinase 1 (Pak1) signaling influences therapeutic outcome in pancreatic cancer.
Ann Oncol. 2016; 27(8): 1546-1556. Doi: 10.1093/annonc/mdw184 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Rack, B; Jückstock, J; Trapp, E; Weissenbacher, T; Alunni-Fabbroni, M; Schramm, A; Widschwendter, P; Lato, K; Zwingers, T; Lorenz, R; Tesch, H; Schneeweiss, A; Fasching, P; Mahner, S; Beckmann, MW; Lichtenegger, W; Janni, W; SUCCESS Study Group CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients.
Tumour Biol. 2016; 37(10):13769-13775 Doi: 10.1007/s13277-016-5171-2
Web of Science PubMed FullText FullText_MUG


Sehouli, J; Chekerov, R; Reinthaller, A; Richter, R; Gonzalez-Martin, A; Harter, P; Woopen, H; Petru, E; Hanker, LC; Keil, E; Wimberger, P; Klare, P; Kurzeder, C; Hilpert, F; Belau, AK; Zeimet, A; Bover-Barcelo, I; Canzler, U; Mahner, S; Meier, W Topotecan plus carboplatin versus standard therapy with paclitaxel plus carboplatin (PC) or gemcitabine plus carboplatin (GC) or pegylated liposomal doxorubicin plus carboplatin (PLDC): a randomized phase III trial of the NOGGO-AGO-Study Group-AGO Austria and GEICO-ENGOT-GCIG intergroup study (HECTOR).
Ann Oncol. 2016; 27(12):2236-2241 Doi: 10.1093/annonc/mdw418 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Wilson, JM; Fokas, E; Dutton, SJ; Patel, N; Hawkins, MA; Eccles, C; Chu, KY; Durrant, L; Abraham, AG; Partridge, M; Woodward, M; O'Neill, E; Maughan, T; McKenna, WG; Mukherjee, S; Brunner, TB ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer.
Radiother Oncol. 2016; 119(2):306-11 Doi: 10.1016/j.radonc.2016.03.021 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Mayr, C; Neureiter, D; Pichler, M; Berr, F; Wagner, A; Kiesslich, T; Namberger, K Cytotoxic effects of chemokine receptor 4 inhibition by AMD3100 in biliary tract cancer cells: Potential drug synergism with gemcitabine.
Mol Med Rep. 2015; 12(2):2247-2252 Doi: 10.3892/mmr.2015.3589 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG


Widschwendter, P; Friedl, TW; Schwentner, L; DeGregorio, N; Jaeger, B; Schramm, A; Bekes, I; Deniz, M; Lato, K; Weissenbacher, T; Kost, B; Andergassen, U; Jueckstock, J; Neugebauer, J; Trapp, E; Fasching, PA; Beckmann, MW; Schneeweiss, A; Schrader, I; Rack, B; Janni, W; Scholz, C The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial.
Breast Cancer Res. 2015; 17(4):129-129 Doi: 10.1186/s13058-015-0639-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Forster, T; Rausch, V; Zhang, Y; Isayev, O; Heilmann, K; Schoensiegel, F; Liu, L; Nessling, M; Richter, K; Labsch, S; Nwaeburu, CC; Mattern, J; Gladkich, J; Giese, N; Werner, J; Schemmer, P; Gross, W; Gebhard, MM; Gerhauser, C; Schaefer, M; Herr, I Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.
Oncotarget. 2014; 5(6):1621-1634 Doi: 10.18632/oncotarget.1764 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Hofmann, H; von Haken, R; Werner, J; Kortes, N; Bergmann, F; Schemmer, P; Jäger, D; Radeleff, B; Schulze-Bergkamen, H Unresectable isolated hepatic metastases from solid pseudopapillary neoplasm of the pancreas: a case report of chemosaturation with high-dose melphalan.
Pancreatology. 2014; 14(6):546-549 Doi: 10.1016/j.pan.2014.08.006 (- Case Report)
Web of Science PubMed FullText FullText_MUG


Pink, D; Richter, S; Gerdes, S; Andreou, D; Tunn, PU; Busemann, C; Ehninger, G; Reichardt, P; Schuler, MK Gemcitabine and docetaxel for epithelioid sarcoma: results from a retrospective, multi-institutional analysis.
Oncology. 2014; 87(2): 95-103. Doi: 10.1159/000362602
Web of Science PubMed FullText FullText_MUG



Lin, S; Hoffmann, K; Xiao, Z; Jin, N; Galli, U; Mohr, E; Büchler, MW; Schemmer, P MEK inhibition induced downregulation of MRP1 and MRP3 expression in experimental hepatocellular carcinoma.
Cancer Cell Int. 2013; 13(1):3-3 Doi: 10.1186/1475-2867-13-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Fokas, E; Prevo, R; Pollard, JR; Reaper, PM; Charlton, PA; Cornelissen, B; Vallis, KA; Hammond, EM; Olcina, MM; Gillies, McKenna, W; Muschel, RJ; Brunner, TB Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation.
Cell Death Dis. 2012; 3:e441 Doi: 10.1038/cddis.2012.181 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Prevo, R; Fokas, E; Reaper, PM; Charlton, PA; Pollard, JR; McKenna, WG; Muschel, RJ; Brunner, TB The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy.
Cancer Biol Ther. 2012; 13(11):1072-81 Doi: 10.4161/cbt.21093 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Brunner, TB; Sauer, R; Fietkau, R Gemcitabine/cisplatin versus 5-fluorouracil/mitomycin C chemoradiotherapy in locally advanced pancreatic cancer: a retrospective analysis of 93 patients.
Radiat Oncol. 2011; 6:88 Doi: 10.1186/1748-717X-6-88 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Schwarzenberg, J; Radu, CG; Benz, M; Fueger, B; Tran, AQ; Phelps, ME; Witte, ON; Satyamurthy, N; Czernin, J; Schiepers, C Human biodistribution and radiation dosimetry of novel PET probes targeting the deoxyribonucleoside salvage pathway.
Eur J Nucl Med Mol Imaging. 2011; 38(4):711-721 Doi: 10.1007/s00259-010-1666-z [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG



Hoffmann, K; Franz, C; Xiao, Z; Mohr, E; Serba, S; Büchler, MW; Schemmer, P Sorafenib modulates the gene expression of multi-drug resistance mediating ATP-binding cassette proteins in experimental hepatocellular carcinoma.
Anticancer Res. 2010; 30(11):4503-4508
Web of Science PubMed



Kallifatidis, G; Rausch, V; Baumann, B; Apel, A; Beckermann, BM; Groth, A; Mattern, J; Li, Z; Kolb, A; Moldenhauer, G; Altevogt, P; Wirth, T; Werner, J; Schemmer, P; Büchler, MW; Salnikov, AV; Herr, I Sulforaphane targets pancreatic tumour-initiating cells by NF-kappaB-induced antiapoptotic signalling.
Gut. 2009; 58(7):949-963 Doi: 10.1136/gut.2008.149039
Web of Science PubMed FullText FullText_MUG



Brunner, TB; Geiger, M; Grabenbauer, GG; Lang-Welzenbach, M; Mantoni, TS; Cavallaro, A; Sauer, R; Hohenberger, W; McKenna, WG Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer.
J Clin Oncol. 2008; 26(16):2699-706 Doi: 10.1200/JCO.2007.15.2355
Web of Science PubMed FullText FullText_MUG


Skoda, C; Erovic, BM; Wachek, V; Vormittag, L; Wrba, F; Martinek, H; Heiduschka, G; Kloimstein, P; Selzer, E; Thurnher, D Down-regulation of Mcl-1 with antisense technology alters the effect of various cytotoxic agents used in treatment of squamous cell carcinoma of the head and neck.
Oncol Rep. 2008; 19(6):1499-1503
Web of Science PubMed



Brunner, TB; Tinkl, D; Grabenbauer, GG; Meyer, T; Brueckl, WM; Sauer, R Maintenance chemotherapy after chemoradiation improves survival of patients with locally advanced pancreatic carcinoma - A retrospective analysis of prospectively recruited patients
STRAHLENTHER ONKOL. 2006; 182(4): 210-215. Doi: 10.1007/s00066-006-1524-x
Web of Science PubMed FullText FullText_MUG


Friess, H; Langrehr, JM; Oettle, H; Raedle, J; Niedergethmann, M; Dittrich, C; Hossfeld, DK; Stoger, H; Neyns, B; Herzog, P; Piedbois, P; Dobrowolski, F; Scheithauer, W; Hawkins, R; Katz, F; Balcke, P; Vermorken, J; van Belle, S; Davidson, N; Esteve, AA; Castellano, D; Kleeff, J; Tempia-Caliera, AA; Kovar, A; Nippgen, J A randomized multi-center phase II trial of the angiogenesis inhibitor Cilengitide (EMD 121974) and gemcitabine compared with gemcitabine alone in advanced unresectable pancreatic cancer
BMC CANCER. 2006; 6: 285 Doi: 10.1186/1471-2407-6-285 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG


Petru, E; Angleitner-Boubenizek, L; Reinthaller, A; Deibl, M; Zeimet, AG; Volgger, B; Stempfl, A; Marth, C Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum-taxane therapy: a phase II Austrian AGO study.
Gynecol Oncol. 2006; 102(2):226-229 Doi: 10.1016/j.ygyno.2005.12.017
Web of Science PubMed FullText FullText_MUG Google Scholar


Wobser, M; Keikavoussi, P; Kunzmann, V; Weininger, M; Andersen, MH; Becker, JC Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin.
Cancer Immunol Immunother. 2006; 55(10):1294-1298 Doi: 10.1007/s00262-005-0102-x (- Case Report)
Web of Science PubMed FullText FullText_MUG Google Scholar



Brunner, TB; Grabenbauer, GG; Klein, P; Baum, U; Papadopoulos, T; Bautz, W; Hohenberger, W; Sauer, R Phase I trial of strictly time-scheduled gemcitabine and cisplatin with concurrent radiotherapy in patients with locally advanced pancreatic cancer.
Int J Radiat Oncol Biol Phys. 2003; 55(1):144-53 Doi: 10.1016/s0360-3016(02)03818-x
Web of Science PubMed FullText FullText_MUG


Pföhler, C; Cree, IA; Ugurel, S; Kuwert, C; Haass, N; Neuber, K; Hengge, U; Corrie, PG; Zutt, M; Tilgen, W; Reinhold, U Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study.
Anticancer Drugs. 2003; 14(5):337-340 Doi: 10.1097/01.cad.0000070764.25457.ce
Web of Science PubMed FullText FullText_MUG Google Scholar


Ugurel, S; Tilgen, W; Reinhold, U Chemosensitivity testing in malignant melanoma.
Recent Results Cancer Res. 2003; 161(8):81-92 Doi: 10.1007/978-3-642-19022-3_8
PubMed FullText FullText_MUG



Fargnoli, MC; Peris, K; Francesconi, F; Cantonetti, M; Cerroni, L; Chimenti, S Granulomatous mycosis fungoides responsive to gemcitabine.
Eur J Dermatol. 2002; 12(5):479-481 (- Case Report) [OPEN ACCESS]
Web of Science PubMed


© Med Uni Graz Impressum